Kappelmann et al. in a meta-analysis showed that adalimumab, etanercept, infliximab and tocilizumab had beneficial effect in depressive symptomatology, in a variety of immune-mediated diseases.94 Interestingly, in a recent mega-analysis it was found that IL-12/-23 and IL-6 blockers demonstrated larger effects on depression occurring in immune-mediated diseases, compared to other bDMARDs.95 Here, IL6 is linked to major depressive disorder.